AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet. ZALVISO is a pre-programmed and patient-controlled analgesia system.
Market Cap | 9.477 Million | Shares Outstanding | 16.34 Million | Avg 30-day Volume | 360.759 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | 8.58 |
Price to Revenue | 26.9634 | Debt to Equity | 0.233 | EBITDA | -26.468 Million |
Price to Book Value | 4.3677 | Operating Margin | -1376.6363000000001 | Enterprise Value | 52.169 Million |
Current Ratio | 1.834 | EPS Growth | 0 | Quick Ratio | 1.411 |
1 Yr BETA | -4.3619 | 52-week High/Low | 4.86 / 0.55 | Profit Margin | -1509.1894 |
Operating Cash Flow Growth | 24.5354 | Free Cash Flow to Firm (FCFF) TTM | -100.883 Million | Free Cash Flow to Equity (FCFE) TTM | -15.301 Million |
Altman Z-Score | -23.182 | ||||
Earnings Report | 2023-11-13 |
Please sign in first
10 Thousand total shares from 1 transactions
17 Thousand total shares from 2 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
ANGOTTI VINCENT J. CHIEF EXECUTIVE OFFICER |
|
91,805 | 2023-09-11 | 4 |
PALMER PAMELA P CHIEF MEDICAL OFFICER |
|
30,753 | 2023-08-24 | 4 |
DASU BADRI N CHIEF ENGINEERING OFFICER |
|
18,771 | 2023-03-03 | 3 |
ASADORIAN RAFFI CHIEF FINANCIAL OFFICER |
|
22,081 | 2023-03-03 | 3 |
|
67,750 | 2022-07-15 | 0 | |
|
67,750 | 2022-07-15 | 0 | |
|
242,750 | 2022-07-15 | 0 | |
|
61,500 | 2022-07-15 | 0 | |
|
125,250 | 2022-07-15 | 0 | |
|
68,750 | 2022-07-15 | 0 | |
|
71,500 | 2022-07-15 | 0 | |
|
281,250 | 2021-06-17 | 0 | |
HAMEL LAWRENCE G CHIEF DEVELOPMENT OFFICER |
|
157,564 | 2020-02-11 | 0 |
|
0 | 2018-06-14 | 0 | |
|
0 | 2018-05-21 | 0 | |
SAIA JOHN G. GENERAL COUNSEL AND SECRETARY |
|
0 | 2018-04-16 | 0 |
|
No longer subject to file | 2017-06-19 | 0 | |
MORRIS TIMOTHY E CHIEF FINANCIAL OFFICER |
|
0 | 2017-02-07 | 0 |
MITCHELL JANE WRIGHT CHIEF LEGAL OFFICER |
|
0 | 2017-02-07 | 0 |
YATRA ONLINE, INC. CHIEF FINANCIAL OFFICER |
|
0 | 2014-03-25 | 0 |
SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P |
|
No longer subject to file | 2014-03-07 | 0 |
|
134,567 | 2014-03-02 | 0 | |
WELCH JAMES H CHIEF FINANCIAL OFFICER |
|
0 | 2014-02-04 | 0 |
CHUNG DAVID CHIEF COMMERCIAL OFFICER |
|
0 | 2014-02-04 | 0 |
|
2,507,974 | 2013-09-19 | 0 | |
|
0 | 2012-07-24 | 0 | |
|
8,206,351 | 2012-05-29 | 0 | |
SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P |
|
4,418,161 | 2012-05-29 | 0 |
|
0 | 2011-02-16 | 0 | |
|
0 | 2011-02-16 | 0 | |
|
8,177,073 | 2011-02-16 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANGOTTI VINCENT J. - Director - Officer CHIEF EXECUTIVE OFFICER |
2023-09-11 19:13:26 -0400 | 2023-09-11 | P | 10,000 | $0.80 | a | 91,805 | direct | -7.151 | -9.1941 | 4.4268 | 4 | -9.1941 | 6 | ||
2023-08-25 16:45:44 -0400 | 2023-08-25 | S | 7,442 | $1.09 | d | 30,753 | direct | 4.3478 | 7.3913 | 13.0435 | 3 | 0.0 | 1 | |||
2023-08-25 16:45:44 -0400 | 2023-08-24 | S | 9,514 | $1.17 | d | 38,195 | direct | 4.3478 | 7.3913 | 13.0435 | 3 | 0.0 | 1 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 22:15:03 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 21:45:03 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 21:15:04 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 20:45:04 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 20:15:03 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 19:45:03 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 19:15:03 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 18:45:04 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 18:15:04 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 17:45:04 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 17:15:03 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 16:45:04 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 16:15:04 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 15:45:04 UTC | -7.6534 | 12.9734 | 900000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 15:15:04 UTC | -7.6534 | 12.9734 | 850000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 14:45:03 UTC | -7.6534 | 12.9734 | 850000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 14:15:03 UTC | -7.6534 | 12.9734 | 850000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 13:45:04 UTC | -7.9203 | 13.2403 | 850000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 13:15:05 UTC | -7.9203 | 13.2403 | 600000 |
ACELRX PHARMACEUTICALS INC ACRX | 2023-10-02 12:45:05 UTC | -7.9203 | 13.2403 | 600000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | ACRX | -970.0 shares, $-1076.7 | 2023-06-30 | N-PORT |